Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesInfectious Agent Antigen DetectionCPT cpt-87635-sars-cov-2-molecular-detection-amplified-nucleic-acid
    Ask Trek AI about this page

    CPT 87635: SARS‑CoV‑2 Amplified Nucleic Acid Detection

    Commercial payers pay $58 on average nationally for this procedure.

    CPT code 87635 describes a laboratory test that uses an amplified nucleic acid probe technique to detect nucleic acids from severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), the virus that causes COVID-19; service type: molecular diagnostic (nucleic acid amplification) testing; typical site of service: clinical laboratory or high‑complexity testing facility.

    For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.

    Customize your policy alerts

    Sign up for cpt 87635 policy alerts

    Get alerted when payer policies referencing 87635 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    BUCA’s average commercial rate of $57.9 for CPT 87635 sits near the center of the market, offering a useful baseline against which individual payer distributions diverge. Blue Cross Blue Shield’s interquartile spread (P75–P25) is $17.5, UnitedHealth Group’s spread is $20.5, and Aetna’s spread is $20.0; Cigna’s spread is the widest at $34.3. These differences indicate varying contract tightness around their medians and suggest more predictable payment bands for Blue Cross Blue Shield compared with Cigna.

    In level terms, Aetna and Blue Cross Blue Shield have higher median or mean touchpoints than UnitedHealth Group and Cigna, while BUCA’s mean remains squarely mid-market. Cigna’s large P75–P25 gap of $34.3 reflects the greatest dispersion among the listed commercial payers, whereas Blue Cross Blue Shield’s $17.5 interquartile range is the tightest, implying more concentrated commercial rates for CPT 87635.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 42-year-old outpatient presents to a community urgent care clinic with 2 days of fever, cough, and myalgia. The clinician documents acute respiratory symptoms and orders a molecular SARS–CoV–2 test. A nasopharyngeal or anterior nasal swab is collected per facility protocol and sent to the on-site or reference laboratory. The laboratory performs an amplified nucleic acid probe technique to detect SARS–CoV‑2 RNA, consistent with 87635. Results are reported electronically to the ordering clinician and public health authorities when required. Typical workflow steps: specimen collection and labeling, transport to laboratory, accessioning, nucleic acid extraction (if required), amplified probe assay run, result validation by the laboratory analyst, and reporting of a positive, negative, or inconclusive result. Applicable encounter contexts include diagnostic testing for symptomatic patients (U07.1, J12.82), testing after exposure (Z20.822), screening encounters (Z11.52), or follow-up documentation of prior infection (Z86.16). Typical sites of service: ambulatory clinics, urgent care centers, hospital outpatient laboratories, and commercial reference laboratories performing molecular COVID‑19 testing.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure

    Related Modifiers

    8 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    95Modifier 95 indicates that a service was provided via synchronous, real‑time audio‑video telehealth rather than in‑person. Per CMS, AAPC and professional associations, append modifier 95 to claim…- Use modifier 95 to indicate a service was furnished via synchronous, real‑time audiovisual telehealth (a live audio‑video conference between patient and provider) rather than in‑person. - Pair…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    76Modifier -76, Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional, is appended when the same provider performs an identical, medically necessary procedure or…- Use modifier -76 when the same physician or other qualified health care professional performs an identical procedure or service a second (or subsequent) time on the same date of service and the…
    77Modifier 77 indicates that a previously performed procedure or service was legitimately repeated by a different physician or other qualified health care professional. The AMA’s CPT definition…- Use modifier 77 when a basic procedure or service already performed is repeated by a different physician or other qualified health care professional (for example, a second provider independently…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    246ZE0500X
    207VE0102X
    2251X0800X
    261QP0904X
    163WN1003X
    2080P1004X
    364SF0001X
    2084H0002X

    Related ICD-10-CM Codes

    27 rows

    ICD-10-CM CodeDescription
    A41.9Sepsis, unspecified organism
    B97.29Other coronavirus as the cause of diseases classified elsewhere
    E11.9Type 2 diabetes mellitus without complications
    F41.9Anxiety disorder, unspecified
    I10Essential (primary) hypertension
    J06.9Acute upper respiratory infection, unspecified
    J12.82Pneumonia due to coronavirus disease 2019
    J18.9Pneumonia, unspecified organism
    J80Acute respiratory distress syndrome
    J96.00Acute respiratory failure, unspecified whether with hypoxia or hypercapnia

    Showing 1–10 of 27

    Related Payer Policy Updates

    Specialty: Infectious Disease1 / 3

    10 rows

    PolicyPayerEffective Date
    Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    HIV/AIDS Pharmacologic Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    Long-Acting Injectable Antiretroviral Agents for HIVColorado Rocky Mountain Health Plans2026-10-01
    B-Hemolytic Streptococcus TestingOscar Health2026-10-01
    Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance AssaysOscar Health2026-10-01
    Hepatitis Testing (A, B, C, D) Coverage CriteriaOscar Health2026-10-01
    Lyme Disease Testing Coverage CriteriaOscar Health2026-10-01
    Pathogen Panel TestingOscar Health2026-10-01
    Diagnostic Testing of Common Sexually Transmitted InfectionsOscar Health2026-10-01
    Testing for Diagnosis of Active or Latent TuberculosisOscar Health2026-10-01

    Related Codes

    CPT-87260-ADENOVIRUS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87260: Adenovirus Antigen Detection by Immunofluorescence

    CPT-87265-BORDETELLA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87265: Bordetella Antigen Detection by Immunofluorescence

    CPT-87267-ENTEROVIRUS-DFA-ANTIGEN-DETECTION

    CPT 87267: Enterovirus Antigen Detection by DFA

    CPT-87269-GIARDIA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87269: Giardia Antigen Detection by Immunofluorescence

    CPT-87270-CHLAMYDIA-TRACHOMATIS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87270: Chlamydia trachomatis Antigen Detection by Immunofluorescence

    CPT-87271-CMV-DFA-ANTIGEN-DETECTION

    CPT 87271: CMV Antigen Detection by Direct Fluorescent Antibody

    CPT-87272-CRYPTOSPORIDIUM-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87272: Cryptosporidium Antigen Immunofluorescent Test

    CPT-87273-HSV-2-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87273: HSV-2 Antigen Detection by Immunofluorescence

    CPT-87274-HSV-1-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87274: HSV-1 Antigen Detection by Immunofluorescence

    CPT-87275-INFLUENZA-B-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87275: Influenza B Antigen Detection by Immunofluorescence

    Showing 1–10 of 167

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    U0003High‑throughput SARS‑CoV‑2 nucleic acid detectionCrosswalk related: used for high-throughput platform testing for SARS‑CoV‑2; may be reported by high-volume reference labs as alternate coding.
    U0002Non‑CDC SARS‑CoV‑2 testingHCPCS code for non‑CDC assays for SARS‑CoV‑2 nucleic acid detection; used by laboratories when 87635 is not the selected molecular CPT or when payor instructions require HCPCS coding.